drugset / Trial / NCT00515528

Vaccination Plus Ontak in Patients With Metastatic Melanoma

NCT00515528

Phase 2 Terminated 17 enrolled University of Chicago Eisai Inc. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if an experimental melanoma vaccine can produce an immune response in patients with metastatic melanoma, and if combining this vaccine with the drug Ontak can improve these immune responses. It is also hoped that this will lead to tumor shrinkage.

Timeline

Start
2007-04-23
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject 4-peptide melanoma vaccine Vaccine 125 ug Subcutaneous
Subject 4-peptide melanoma vaccine Vaccine 250 ug Subcutaneous
Subject denileukin diftitox Protein / enzyme biologic 18 ug/kg Intravenous

Indications